Related Experiment Video

Updated: Jun 21, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Treating patients with severe heart failure

Eric J Eichhorn1

  • 1University of Colorado Health Science Center, Denver, Colorado, USA. eeichhorn@csant.com

Postgraduate Medicine
|August 12, 2009
PubMed

Insights

Beta-blockers are crucial for managing heart failure, improving cardiac function and outcomes. This review examines clinical trials focusing on beta-blockers in patients with severe heart failure (NYHA class IV).

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • The renin-angiotensin and sympathetic nervous systems significantly contribute to heart failure progression.
  • Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are proven to mitigate cardiac remodeling, enhancing heart function and patient outcomes.
  • Standard heart failure treatment includes diuretics, ACE inhibitors (or ARBs), beta-blockers, and potentially digoxin.

Purpose of the Study:

  • To review clinical trial data on beta-blocker efficacy in patients with severe heart failure (NYHA class IV).
  • To address the less-defined treatment strategies for advanced heart failure stages.

Main Methods:

  • Review of existing clinical trials involving beta-blockers.
  • Focus on trials that included patients with New York Heart Association (NYHA) functional class IV heart failure.

Main Results:

  • Established treatments show benefits for NYHA class II/III heart failure.
  • Limited data exists for NYHA class IV heart failure patients in clinical trials.
  • This review specifically analyzes beta-blocker trials in severe heart failure populations.

Conclusions:

  • Beta-blockers play a vital role in heart failure management.
  • Further research and clinical trial inclusion of severe heart failure patients are needed for optimized treatment protocols.

More Related Videos

Implantation of the Syncardia Total Artificial Heart16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...